Company Overview
Modular Medical, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry through the design, development, and commercialization of insulin pumps for patients with type-1 and type-2 diabetes. The company's core product portfolio includes MODD1, a two-part patch pump engineered to provide flexible delivery solutions for glucose management. As of the latest data, Modular Medical, Inc. maintains a market capitalization of $21.94M and employs 53 individuals across its operations. The company is headquartered in San Diego, California, positioning it within the broader ecosystem of biotechnology and medical technology firms. The current market capitalization of $21.94M suggests a small-cap classification, indicating that the company is still in a phase of scaling operations rather than established dominance, while the absence of reported annual revenue figures highlights the challenges often faced by early-stage medical device companies in generating substantial top-line growth consistent with their market cap. The employee count of 53 reflects a lean organizational structure typical of firms in the development and commercialization stage, where capital efficiency is prioritized over large-scale headcount expansion.
Financial Health
The financial profile of Modular Medical, Inc. reveals a company currently in a loss position, with a net income of $-26,779,000 and an EBITDA of $-25,298,000 over the trailing twelve-month period. The revenue for this period is not available in the reported data, yet the significant net loss relative to the available EBITDA indicates substantial operating expenses or one-time costs that impact the bottom line. Free cash flow stands at $-15,671,375, which signifies that the company is burning cash faster than it generates from its operations, a common characteristic for device developers awaiting product milestones or regulatory approvals. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, indicating that the company has not yet achieved profitability or that revenue figures are insufficient to calculate meaningful margins in the current reporting period. On the balance sheet, the company holds $2.94M in cash against $504,000 in debt, resulting in a debt-to-equity ratio of 8.57, which suggests a highly leveraged position relative to its equity base despite the low absolute debt amount. The current ratio is 1.59, indicating that the company possesses 1.59 times more current assets than current liabilities, which provides a moderate buffer for short-term liquidity obligations. Return on Equity is -331.8% and Return on Assets is -149.8%, revealing that the company's current capital structure is generating significant negative returns, likely due to the heavy investment required in R&D and commercialization that has not yet translated into profitable earnings.
Valuation Assessment
Valuation multiples for Modular Medical, Inc. present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -0.31. The negative forward P/E implies that the market is pricing in potential future earnings recovery or that the stock is valued on a cash-burn basis rather than traditional earnings multiples. The price-to-book ratio is 2.06, suggesting that the market values the company at more than twice its book value, which may reflect intangible assets like intellectual property or the potential future value of the insulin pump portfolio. Alternative valuation metrics include a price-to-sales ratio of N/A and an EV/EBITDA of -0.39, both of which underscore the company's immaturity and the difficulty in applying standard valuation models to a pre-profitability medical device firm. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $1.29 and a 52-week low of $0.12. Based on the provided data points, the current valuation context must be understood within this wide range, where the stock has demonstrated resilience below the $1.29 high but remains above the $0.12 low. The beta of -0.14 is an unusual metric for equities, indicating an inverse relationship to the broader market or high idiosyncratic volatility that does not correlate positively with market movements.
Growth & Income
Modular Medical, Inc. reports revenue growth of N/A and earnings growth of N/A over the year-over-year period, as the company has not yet reached a stage where comparable growth rates can be calculated from the available financial history. Consequently, it is not possible to determine whether earnings are growing faster or slower than revenue, as the foundational data for such a comparison is absent from the financial statements. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings, or rather, the reinvested capital, are directed back into business operations rather than distributed to shareholders. This reinvestment strategy is typical for medical device companies focused on R&D and bringing new technologies like the MODD1 patch pump to market, prioritizing product development over immediate income generation for investors. The overall growth and income profile is characterized by a focus on capital preservation and operational scaling rather than income generation or dividend payouts.